1. Home
  2. PBYI vs LANV Comparison

PBYI vs LANV Comparison

Compare PBYI & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • LANV
  • Stock Information
  • Founded
  • PBYI 2010
  • LANV 2015
  • Country
  • PBYI United States
  • LANV China
  • Employees
  • PBYI N/A
  • LANV N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • LANV Blank Checks
  • Sector
  • PBYI Health Care
  • LANV Finance
  • Exchange
  • PBYI Nasdaq
  • LANV Nasdaq
  • Market Cap
  • PBYI 153.2M
  • LANV 219.4M
  • IPO Year
  • PBYI N/A
  • LANV N/A
  • Fundamental
  • Price
  • PBYI $3.09
  • LANV $1.85
  • Analyst Decision
  • PBYI Strong Buy
  • LANV
  • Analyst Count
  • PBYI 1
  • LANV 0
  • Target Price
  • PBYI $7.00
  • LANV N/A
  • AVG Volume (30 Days)
  • PBYI 754.5K
  • LANV 92.6K
  • Earning Date
  • PBYI 02-27-2025
  • LANV 02-19-2025
  • Dividend Yield
  • PBYI N/A
  • LANV N/A
  • EPS Growth
  • PBYI 492.79
  • LANV N/A
  • EPS
  • PBYI 0.47
  • LANV N/A
  • Revenue
  • PBYI $243,569,000.00
  • LANV $409,961,427.00
  • Revenue This Year
  • PBYI N/A
  • LANV N/A
  • Revenue Next Year
  • PBYI N/A
  • LANV $10.45
  • P/E Ratio
  • PBYI $6.63
  • LANV N/A
  • Revenue Growth
  • PBYI 6.30
  • LANV N/A
  • 52 Week Low
  • PBYI $2.23
  • LANV $0.91
  • 52 Week High
  • PBYI $7.73
  • LANV $3.78
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 49.17
  • LANV 46.31
  • Support Level
  • PBYI $2.92
  • LANV $1.69
  • Resistance Level
  • PBYI $4.06
  • LANV $2.09
  • Average True Range (ATR)
  • PBYI 0.29
  • LANV 0.24
  • MACD
  • PBYI 0.01
  • LANV -0.04
  • Stochastic Oscillator
  • PBYI 27.07
  • LANV 25.97

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.

Share on Social Networks: